Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 14501 - 14525 of 15238 in total
Sotevtamab is under investigation in clinical trial NCT06225843 (Sotevtamab (AB-16B5) Combined With FOLFOX as Neoadjuvant Treatment Prior to Resection of Colorectal Cancer Liver Metastasis).
Investigational
Investigational
Ovemotide is under investigation in clinical trial NCT00357461 (Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV Melanoma).
Investigational
ATG002 is a completely new approach to treating chronic wounds such as diabetic foot ulcers, which is based upon stimulation of angiogenesis in the wound bed to help drive the wound-healing process. Unlike protein-derived growth factors, ATG002 is a small molecule that, applied topically, effectively penetrates through the wound and...
Investigational
Matched Description: … factors, ATG002 is a small molecule that, applied topically, effectively penetrates through the wound and
CAM2029 is a new ready-to-use, long-acting octreotide formulation being developed for the long-term treatment of acromegaly, carcinoid syndrome and vasoactive intestinal peptide (VIP)-producing tumours. CAM2029 was found to provide long-acting release of octreotide resulting in a statistically significant suppression of a clinical biomarker insulin-like growth factor 1 (IGF-1) over the...
Investigational
Matched Description: … octreotide formulation being developed for the long-term treatment of acromegaly, carcinoid syndrome and
Zosuquidar is a compound of antineoplastic drug candidates currently under development. It is now in "Phase 3" of clinical tests in the United States. Its action mechanism consists of the inhibition of P-glycoproteins; other drugs with this mechanism include tariquidar and laniquidar.
Investigational
Matched Description: … mechanism consists of the inhibition of P-glycoproteins; other drugs with this mechanism include tariquidar and
Investigational
Investigational
Perflubron (Oxygent) is being developed as an intravascular oxygen carrier designed to augment oxygen delivery in surgical patients.
Investigational
AV608 is a NK-1 antagonist. It is developed for the treatment of Social anxiety disorder (SAD), irritable bowel syndrome (IBS) and overactive bladder (OAB).
Investigational
Matched Description: … It is developed for the treatment of Social anxiety disorder (SAD), irritable bowel syndrome (IBS) and
Cetilistat is a novel inhibitor of pancreatic lipase being developed by Alizyme for the treatment of obesity and associated co-morbidities, including type 2 diabetes.
Investigational
Matched Description: … Cetilistat is a novel inhibitor of pancreatic lipase being developed by Alizyme for the treatment of obesity and
MK0249 has been used in trials studying the treatment of Hypopnea Syndrome, Alzheimer's Disease, Paranoid Schizophrenia, Sleep Apnea, Obstructive, and Excessive Daytime Sleepiness, among others.
Investigational
Matched Description: … treatment of Hypopnea Syndrome, Alzheimer's Disease, Paranoid Schizophrenia, Sleep Apnea, Obstructive, and
Entospletinib has been used in trials studying the treatment of Oncology, Follicular Lymphoma, B-cell Malignancies, Mantle Cell Lymphoma, and Non-Hodgkin Lymphoma, among others.
Investigational
Matched Description: … studying the treatment of Oncology, Follicular Lymphoma, B-cell Malignancies, Mantle Cell Lymphoma, and
Litoxetine is under investigation in clinical trial NCT03397771 (DBPC Trial to Evaluate the Safety, Tolerability and Efficacy of Oral Litoxetine in Subjects With Urinary Incontinence).
Investigational
Matched Description: … under investigation in clinical trial NCT03397771 (DBPC Trial to Evaluate the Safety, Tolerability and
MK-6325 is under investigation in clinical trial NCT01329913 (Safety, Pharmacokinetics, and Pharmacodynamics of MK-6325 in Hepatitis C Virus (HCV) Infections (MK-6325-003)).
Investigational
Matched Description: … MK-6325 is under investigation in clinical trial NCT01329913 (Safety, Pharmacokinetics, and Pharmacodynamics …
Ensifentrine is under investigation in clinical trial NCT04535986 (A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD).
Investigational
Matched Description: … under investigation in clinical trial NCT04535986 (A Phase 3 Clinical Trial to Evaluate the Safety and
Olacaftor is under investigation in clinical trial NCT02951182 (A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic Fibrosis).
Investigational
Matched Description: … Olacaftor is under investigation in clinical trial NCT02951182 (A Study Evaluating the Safety and Efficacy …
Deudomperidone is under investigation in clinical trial NCT05832151 (A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis).
Investigational
Matched Description: … Deudomperidone is under investigation in clinical trial NCT05832151 (A Study to Evaluate the Efficacy and
Arketamine is under investigation in clinical trial NCT05414422 (A Randomized, Placebo-controlled, Double-blind Study to Assess Safety and Efficacy of PCN-101 in TRD).
Investigational
Matched Description: … in clinical trial NCT05414422 (A Randomized, Placebo-controlled, Double-blind Study to Assess Safety and
CMC 001 is an orally administered MRI contrast agent in development for enhancement of the liver, bile ducts and gastrointestinal tract.
Investigational
Matched Description: … is an orally administered MRI contrast agent in development for enhancement of the liver, bile ducts and
Fludeoxyglucose is under investigation in clinical trial NCT03262389 (Comparison of F-18 FDG and C-11 Acetate PET in Multiple Myeloma).
Investigational
Matched Description: … Fludeoxyglucose is under investigation in clinical trial NCT03262389 (Comparison of F-18 FDG and C-11 …
Fosmanogepix is under investigation in clinical trial NCT03604705 (An Efficacy and Safety Study of APX001 in Non-Neutropenic Patients With Candidemia).
Investigational
Matched Description: … Fosmanogepix is under investigation in clinical trial NCT03604705 (An Efficacy and Safety Study of APX001 …
U-0126 is a direct inhibitor of the mitogen-activated protein-kinase kinase family members, MEK-1 and MEK-2.
Investigational
Matched Description: … U-0126 is a direct inhibitor of the mitogen-activated protein-kinase kinase family members, MEK-1 and
Emprumapimod is a potent, orally active and selective inhibitor of p38α mitogen-activated kinase inhibitor. It was investigated for dilated cardiomyopathy.
Investigational
Matched Description: … Emprumapimod is a potent, orally active and selective inhibitor of p38α mitogen-activated kinase inhibitor …
Displaying drugs 14501 - 14525 of 15238 in total